Abstract: The present invention is directed at poly(ethylene terephthalate)-poly(ethylene naphthalate (PET-PEN) copolymer extruded sheet that is thermoformable and particularly suitable for medical device packaging, as well as medical device packaging made from such PET-PEN sheet material.

Abstract: The present invention is directed at poly(ethylene terephthalate)-poly(ethylene naphthalate (PET-PEN) copolymer extruded sheet that is thermoformable and particularly suitable for medical device packaging, as well as medical device packaging made from such PET-PEN sheet material.

Abstract: An endoscopic lens cleaning apparatus includes an end cap, a lens, first and second magnets, one or more guide rails to couple housings for the first and second magnets, and a wiper assembly that is attached to and capable of gliding along the guide rail. The wiper assembly houses a wiper magnet that interacts with the first and second magnets. At least one of the wiper magnet or first and second magnets is an electromagnet, coupled to a power supply via a switch. A controller alternates the polarity of current supplied to the electromagnet to cause the wiper assembly to glide along the rail. A wiper attached to the wiper assembly likewise glides along the lens, thereby cleaning it. The controller is programmable, and can operate in continuous, intermittent, or as needed cleaning modes.

Abstract: The invention relates to novel p38 MAPK inhibitor which involves Mycobacterium w and/or its constituents in pharmaceutically acceptable carriers and their uses. Mycobacterium w and/or its constituents when administered to mammal results in p38 inhibition The inhibition is found to last more than 28 days. It is also found to induce inhibition of TNF-? it suppresses cytokines in a pattern identical to Glucocorticoids. In transforms cells it also induces apoptosis. P38 mediated conditions include inflammation, cell differentiation, cell proliferation, cell inhibition, cell cycle regulation, anti-inflammatory reactions, immune modulation, vascularization, response to external stimuli and angiogenesis. The use of Mycobacterium w (Mw) and/or constituents of Mycobacterium w for inhibition of p38 protein kinase i.e. (i) to induce apoptosis in transformed cells (ii) for inhibition of TNF-? (iii) for inhibition of cytokines.

Abstract: The invention relates to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen(s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when administered with antigen(s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition. e.g. immune naïve or preimmunized status.

Abstract: The invention relates to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen (s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when administered with antigen (s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition. e.g. immune naïve or preimmunised status.

Abstract: The invention relates to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen (s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when administered with antigen (s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition. e.g. immune naïve or preimmunized status.

Abstract: The invention relates to novel p38 MAPK inhibitor which involves Mycobacterium w and/or its constituents in pharmaceutically acceptable carriers and their uses. Mycobacterium w and/or its constituents when administered to mammal results in p38 inhibition The inhibition is found to last more than 28 days. It is also found to induce inhibition of TNF-alfa. it suppresses cytokines in a pattern identical to Glucocorticoids. In transforms cells it also induces apoptosis. P38 mediated conditions include inflammation, cell differentiation, cell proliferation, cell inhibition, cell cycle regulation, anti-inflammatory reactions, immune modulation, vascularization, response to external stimuli and angiogenesis. The use of Mycobacterium w (Mw) and/or constituents of Mycobacterium w for inhibition of p38 protein kinase i.e. (i) to induce apoptosis in transformed cells (ii) for inhibition of TNF-alfa (iii) for inhibition of cytokines.

Abstract: The invention relates to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen (s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when administered with antigen (s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition. e.g. immune naïve or preimmunised status.

Abstract: A thermoplastic composition comprising: (i) a thermoplastic resin; (ii) an antiplasticizing amount of a solid plasticizer; (iii) optionally an acid scavenger; and (iv) optionally a heat stabilizer selected from the group consisting of mixed metal stabilizers, organotin stabilizers, lead stabilizers, metal free stabilizers, or any combination of the foregoing which improves the processability of the thermoplastic resin without affecting the physical properties of the thermoplastic resin.

Abstract: The present invention relates to a method of making stabilized halogen containing organic polymer laminate comprising as one layer a halogen-containing organic polymer, an acid scavenger comprising a molecular sieve or zeolite; and a heat stabilizer and as the other layer, a similar composition devoid of a molecular sieve or zeolite.